UL Solutions at Jefferies Global Industrials Conference 2026: growth and margins

UL Solutions reported 2025 revenue of $3.1B, up 6.2% organically, and reaffirmed its 2026 adjusted EBITDA margin target of 27%, up from 21.0% in 2023. Its Industrial segment grew 7.7% organically in 1H 2026, while certification testing rose 10.9% year to date, supported by AI infrastructure, data centers, electrification and automation demand. Management is pruning lower-growth assets while pursuing the Eurofins electrical and electronics acquisition, maintaining roughly 30% ROIC and expecting no leverage increase despite record organic and M&A investment.

Analysis

ULS is increasingly a scarce-play asset-light infrastructure proxy for electrification and AI capex: testing demand monetizes both initial product launches and recurring factory surveillance, while component redesigns create incremental retesting rather than merely shifting end-market volume. The key earnings debate is no longer demand durability but whether current margin gains are structurally repeatable; centralized pricing, lab utilization and portfolio mix can sustain expansion, but incentive compensation shows that quarterly conversion will be uneven.

Near-term, the conference adds little independently verifiable information beyond reaffirmed targets, so a large immediate rerating is unlikely. The 1-3 month catalysts are closing terms and financial disclosure around the Eurofins electrical/electronics acquisition, plus evidence that Industrial growth remains above the corporate rate despite compensation normalization. A successful acquisition would improve European density and potentially lower customer-acquisition costs in smaller accounts; failure to disclose purchase price, expected synergies, or accretion would limit the multiple upside.

The underappreciated second-order benefit is that faster product iteration in AI-enabled hardware, power systems, HVAC and medical devices raises certification intensity per unit even if industrial production softens. Conversely, a broad capex pause by hyperscalers or industrial OEMs would reduce the high-value project pipeline first, while aggressive lab buildout could turn fixed-cost leverage negative. The thesis is falsified by two consecutive quarters of decelerating certification-testing growth, Industrial margin failing to recover after incentive catch-up, or acquisition leverage moving materially higher.

Relative value favors ULS over more cyclical TIC exposure because regulatory complexity and recurring surveillance should dampen volume cyclicality. However, the market may already capitalize a premium quality multiple; add only on post-earnings weakness rather than chase a conference-driven move.

Key Decisions for Investors

• Watch-list long ULS for a 6-18 month compounder position; initiate on a 8-12% pullback or after the next results confirm certification-testing growth remains high single digit or better. Target a 15-25% total-return profile from sustained organic growth plus further margin/quality-multiple support; exit if the two-quarter falsification criteria emerge.
• Before committing capital, require acquisition disclosures: purchase consideration, expected revenue/EBITDA contribution, integration costs, synergy timing and pro forma leverage. If the deal is cash-flow accretive within 12-18 months without leverage expansion, increase position sizing; absent those data, treat as a catalyst watch item rather than a recommendation.
• Pair-trade candidate over 3-6 months: long ULS / short XLI, sized beta-neutral. The pair expresses certification-intensity and pricing resilience versus broad industrial exposure; stop out if global industrial PMIs reaccelerate while ULS certification growth decelerates, undermining the defensive-growth differential.
• Do not infer a trade in AAPL or CRM from this event. Their references are thematic only; there is no disclosed customer, contract, or revenue linkage sufficient to support a differentiated earnings view.